Home News Article Sanofi Issues Voluntary Recall Of Epinephrine Injectors For Severe Allergy
Sanofi Issues Voluntary Recall Of Epinephrine Injectors For Severe Allergy
Kath C. Eustaquio-Derla August 20, 2017 0
30 October 2015, 8:34 am EDT
By Katherine Derla Tech Times
French drug maker Sanofi-Aventis recalls Auvi-Q and Allerject in U.S. and Canada for alleged inaccurate doses. The two products are staples in anaphylaxis first aid, wherein an incorrect dosage could be fatal. ( Sanofi Canada Website )
French pharmaceutical giant Sanofi-Aventis (S.A.) is recalling their Auvi-Q and Allerject auto-injectors in the United States (U.S.) and Canada, respectively for potentially inaccurate doses. Used for the treatment of anaphylaxis, a life-threatening allergic reaction, an inaccurate dose administered could be fatal.
On Oct. 28, Sanofi U.S. released the recall statement of Auvi-Q. The action involved pulling out all products covering both 0.15 mg and 0.3 mg varieties among consumers, retailers and hospitals. The recalled Auvi-Q batches include lot number 2299596 through 3037230 with expirations dates covering March 2016 through December 2016.
As of Oct. 26, Sanofi U.S. listed a total of 26 documented cases of supposed device failure out of an estimated 2,784,000 units across North America. To date, the company confirmed that no death reports have been received in the U.S. Sanofi is keeping the U.S. Food and Drug Administration (FDA) up to date with the recall endeavors, which approved Auvi-Q in August 2012.
In Canada, the recall statement was also released on Oct. 28 for the pull out of Allerject, its Canadian counterpart. So far, the Canadian headquarters received nine cases of alleged device malfunctions from an estimated 492,000 units across the country.
In the documented reports, patients experienced hypersensitivity reaction. The French company noted that none of the device malfunctions cases have been confirmed.
"As this is a life-saving device, it is important that consumers understand not only to return the recalled device, but to get a replacement epinephrine auto-injector first," a Sanofi spokeswoman said in an emailed statement.
In both countries, customers are advised to reach their healthcare providers immediately to procure a substitute epinephrine auto-injector. However, since anaphylaxis could develop rapidly, customers should only use the Sanofi epinephrine auto-injectors if not substitute device is at hand and should call 911 or medical emergency services right away.
Customers are also advised to see their doctors should they experience hypersensitivity or any problems associated with the auto-injectors.
By Katherine Derla Tech Times
French drug maker Sanofi-Aventis recalls Auvi-Q and Allerject in U.S. and Canada for alleged inaccurate doses. The two products are staples in anaphylaxis first aid, wherein an incorrect dosage could be fatal. ( Sanofi Canada Website )
French pharmaceutical giant Sanofi-Aventis (S.A.) is recalling their Auvi-Q and Allerject auto-injectors in the United States (U.S.) and Canada, respectively for potentially inaccurate doses. Used for the treatment of anaphylaxis, a life-threatening allergic reaction, an inaccurate dose administered could be fatal.
On Oct. 28, Sanofi U.S. released the recall statement of Auvi-Q. The action involved pulling out all products covering both 0.15 mg and 0.3 mg varieties among consumers, retailers and hospitals. The recalled Auvi-Q batches include lot number 2299596 through 3037230 with expirations dates covering March 2016 through December 2016.
As of Oct. 26, Sanofi U.S. listed a total of 26 documented cases of supposed device failure out of an estimated 2,784,000 units across North America. To date, the company confirmed that no death reports have been received in the U.S. Sanofi is keeping the U.S. Food and Drug Administration (FDA) up to date with the recall endeavors, which approved Auvi-Q in August 2012.
In Canada, the recall statement was also released on Oct. 28 for the pull out of Allerject, its Canadian counterpart. So far, the Canadian headquarters received nine cases of alleged device malfunctions from an estimated 492,000 units across the country.
In the documented reports, patients experienced hypersensitivity reaction. The French company noted that none of the device malfunctions cases have been confirmed.
"As this is a life-saving device, it is important that consumers understand not only to return the recalled device, but to get a replacement epinephrine auto-injector first," a Sanofi spokeswoman said in an emailed statement.
In both countries, customers are advised to reach their healthcare providers immediately to procure a substitute epinephrine auto-injector. However, since anaphylaxis could develop rapidly, customers should only use the Sanofi epinephrine auto-injectors if not substitute device is at hand and should call 911 or medical emergency services right away.
Customers are also advised to see their doctors should they experience hypersensitivity or any problems associated with the auto-injectors.
Related Posts
- Pluto's Moon Charon Is Beautiful And Has Violent Past
- Passenger Nearly Lost Leg After Being Bitten By Flesh-Eating Spider In Qatar Airways Plane
- Comment Moon Express Aims For First Commercial Moon Landing In 2017
- Historic Drought In California Affecting Giant Sequoias
- Scientists Develop Swimsuit For Sea Turtles To Discover Reptile's Diet And Habitat Habits - See more at: http://www.techtimes.com/articles/90849/20151004/scientists-develop-swimsuit-for-sea-turtles-to-discover-reptiles-diet-and-habitat-habits.htm#sthash.0sczpebv.dpuf
- Researchers Create Artificial Teeth That Are As Strong As The Real Ones Using 100-Year Old Technique
- Butchered Remains Of Woolly Mammoth Unearthed From Farmer's Soy Field In Michigan
- Scientists Alarmed Over Number Of Guadalupe Fur Seals Deaths: What Causes The Die-Off?